P-280 Pembrolizumab versus physician-choice chemotherapy for previously treated patients with advanced/metastatic squamous or adenocarcinoma of the esophagus or Siewert I adenocarcinoma of the esophagogastric junction (EGJ): Randomized, phase 3 KEYNOTE-18

Podobne zapisy

• P-279 Pembrolizumab for patients with previously treated metastatic adenocarcinoma or squamous cell carcinoma of the esophagus: phase 2 KEYNOTE-180 study
  od: Manish, Shah, i wsp.
  Wydane: (2016)
• Lymph node dissection for Siewert II esophagogastric junction adenocarcinoma: Erratum
  Wydane: (2017)
• Efficacy and Safety of Pembrolizumab for Heavily Pretreated Patients With Advanced, Metastatic Adenocarcinoma or Squamous Cell Carcinoma of the Esophagus: The Phase 2 KEYNOTE-180 Study
  od: Shah, Manish A., i wsp.
  Wydane: (2018)
• Genetic Alterations in Barrett Esophagus and Adenocarcinomas of the Esophagus and Esophagogastric Junction Region
  od: Wu, Tsung-Teh, i wsp.
  Wydane: (1998)
• Efficacy of distal perigastric lymphadenectomy for Siewert type II adenocarcinoma of the esophagogastric junction
  od: Zonglin Li, i wsp.
  Wydane: (2025-10-01)